Skip to main content
ACG 2025 Annual Meeting Main banner
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Award Winner
ACG Newsworthy Abstract
ACG Newsworthy Abstract
Registration Required
Registration Required
No CME
No CME
On-Demand Video
On-Demand Video
Livestream
Livestream

Monday Poster Session

Category: Biliary/Pancreas

P2267 - An Uncommon Tumor With Devastating Consequences: Lessons From a Case of Metastatic VIPoma

Monday, October 27, 2025
10:30 AM - 4:00 PM MT
Location: Exhibit Hall
Victoria A. Margolis, MD, Abigail Ellington, MD, Danielle Rambuss, MD, William Lippert, MD
Atrium Health Wake Forest Baptist, Winston-Salem, NC

Introduction: VIPomas are rare pancreatic tumors that secrete vasoactive intestinal polypeptide (VIP), a neuropeptide that promotes smooth muscle relaxation, stimulates pancreatic secretion, and suppresses gastric acid. Symptoms include watery diarrhea, hypokalemia, achlorhydria, and flushing. We present a case of metastatic VIPoma complicated by biliary obstruction and hepatorenal syndrome.

Case Description/

Methods: A 51-year-old male presented with a 1-year history of chronic secretory diarrhea, weight loss, and flushing. He had elevated VIP levels and a pancreatic mass with nodal involvement and was diagnosed with metastatic VIPoma. He underwent distal pancreatectomy, splenectomy, and cholecystectomy in 2016. He had multiple recurrences despite somatostatin analogs, PRRT (Lutathera), liver-directed therapies (TACE, ablation), targeted agents, and chemotherapy. In January 2025, he was admitted with CBD obstruction, along with progressive liver involvement and widespread nodal metastasis. He developed acute liver failure, hepatorenal syndrome, electrolyte derangements, and encephalopathy. Due to multiorgan decline, GI intervention was deferred, and he transitioned to hospice.

Discussion: VIPomas are rare (0.05–0.2 cases/million) but can cause life-threatening fluid and electrolyte loss.1,2 Diagnosis is often delayed due to overlap with other diarrheal illnesses; thus, many cases are metastatic at presentation. Localized tumors respond to resection and somatostatin analogs. Metastatic VIPomas require multimodal treatment.3 The liver is the most common metastatic site and may cause hepatic dysfunction or CBD obstruction via compression or invasion. Biliary stenting is unstudied in VIPoma but is often pursued based on outcomes in other cancers.4 This case highlights diagnostic challenges, treatment complexity, and the importance of considering VIPoma in persistent secretory diarrhea.

References:


  1. Smith SL et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. 1998. doi: 10.1067/msy.1998.92005

  2. Helbing A et al. VIPoma StatPearls. Feb 23, 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507698/

  3. Azizian A, König A, Ghadimi M. Treatment options of metastatic and nonmetastatic VIPoma: a review. Nov 2022. doi: 10.1007/s00423-022-02620-7.

  4. De Herder WW, Hofland J. Vasoactive Intestinal Peptide-Secreting Tumor (VIPoma). April 5, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278960/



Disclosures:
Victoria Margolis indicated no relevant financial relationships.
Abigail Ellington indicated no relevant financial relationships.
Danielle Rambuss indicated no relevant financial relationships.
William Lippert indicated no relevant financial relationships.

Victoria A. Margolis, MD, Abigail Ellington, MD, Danielle Rambuss, MD, William Lippert, MD. P2267 - An Uncommon Tumor With Devastating Consequences: Lessons From a Case of Metastatic VIPoma, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.